Bilateral Acute Iris Transillumination Following Coronavirus Disease 2019 Infection
Abstract
Bilateral acute iris transillumination (BAIT) syndrome is an uncommon disorder marked by sudden dispersion of pigment in the anterior chamber, iris sphincter muscle paralysis, and elevated intraocular pressure. This syndrome has been linked to viral infections and the administration of fluoroquinolones such as moxifloxacin. This study presents a case of a 54-year-old male, otherwise in good health, who developed BAIT syndrome 1 week after experiencing an upper respiratory tract infection that followed a coronavirus disease 2019 (COVID-19) diagnosis. The patient was effectively treated with topical prednisolone acetate and antiglaucoma medications. Further studies are required to investigate the relationship between COVID-19 and BAIT to enhance understanding of its pathophysiology.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.